Shopping Cart

Your shopping cart is currently empty

Etalocib

Name: Etalocib
Brand: TargetMol
SKU: T22358
Price: 65 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T22358Cas No. 161172-51-6

Alias VML295, LY293111

Etalocib (LY293111) is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities.

Etalocib

Copy Product Info

😃Good

Purity: 98.21%

Catalog No. T22358Alias VML295, LY293111Cas No. 161172-51-6

Pack Size	Price	USA Warehouse	Global Warehouse
1 mg	$65	In Stock	In Stock
5 mg	$163	In Stock	In Stock
10 mg	$238	In Stock	In Stock
25 mg	$442	In Stock	In Stock
50 mg	$648	In Stock	In Stock
100 mg	$930	In Stock	In Stock
200 mg	$1,250	-	In Stock
1 mL x 10 mM (in DMSO)	$203	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:98.21%

Appearance:Solid

Color:White

Resource Download

COA HNMR LCMS

Product Introduction

Etalocib AI Summary

Etalocib shows significant bioactivities as an inhibitor of leukotriene B4 (LTB4) receptors and related pathways. It displays a high binding affinity towards human neutrophil LTB4 receptors with a Ki of 25.0 nM and against guinea pig lung membrane LTB4 receptors with a Ki of 6.6 nM. The compound also inhibits LTB4-induced calcium mobilization with an IC50 of 20.0 nM. Additionally, it effectively inhibits the expression of human neutrophil integrin CD11b/CD18 with an IC50 of around 3.9 nM in one study and 3.3 nM in another. In vivo studies demonstrated its inhibitory effects on LTB4-induced bronchoconstriction with an ED50 of 0.04 mg/kg intravenously and 0.4 mg/kg orally. These findings suggest potential anti-inflammatory properties of Etalocib through its interactions with LTB4 receptors..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Etalocib (LY293111) is a novel diaryl ether carboxylic acid derivative, is a selective and potent inhibitor of the lipoxygenase pathway either via antagonism of the leukotriene B4 (LTB4) receptor or directly through 5'-lipoxygenase. It has antineoplastic activities.
Synonyms	VML295, LY293111

Chemical Properties

Molecular Weight	544.6
Formula	C₃₃H₃₃FO₆
Cas No.	161172-51-6
Smiles	CCCc1c(OCCCOc2cc(O)c(cc2CC)-c2ccc(F)cc2)cccc1Oc1ccccc1C(O)=O
Relative Density.	1.215g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 100 mg/mL (183.62 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+90% Corn Oil: 3.3 mg/mL (6.06 mM), Sonication is recommended.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	1.8362 mL	9.1811 mL	18.3621 mL	91.8105 mL
5 mM	0.3672 mL	1.8362 mL	3.6724 mL	18.3621 mL
10 mM	0.1836 mL	0.9181 mL	1.8362 mL	9.1811 mL
20 mM	0.0918 mL	0.4591 mL	0.9181 mL	4.5905 mL
50 mM	0.0367 mL	0.1836 mL	0.3672 mL	1.8362 mL
100 mM	0.0184 mL	0.0918 mL	0.1836 mL	0.9181 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc